TITLE

Recently Approved

PUB. DATE
August 2007
SOURCE
Pharmaceutical Representative;Aug2007, Vol. 37 Issue 8, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents a list of approved drugs in the U.S. They include Endometrin (progesterone) vaginal insert from Parsipanny, New Jersey-based Ferring Pharmaceuticals, hypertension drug Exforge from East Hanover, New Jersey-based Novartis Pharmaceuticals Corp., and Frazer, Pennsylvania-based Cephalon Inc.'s Nuvigil (armodafinil).
ACCESSION #
25963841

 

Related Articles

  • Alzheimer's patients now have a topical option.  // Drug Topics;7/23/2007, Vol. 151 Issue 14, p6 

    The article evaluates Novartis Pharmaceuticals Corp.'s Exelon® Patch Rivastigmine transdermal system for the treatment of Alzheimer's disease.

  • FDA approves new quadrivalent meningococcal vaccine. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/1/2010, Vol. 67 Issue 7, p504 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to the quadrivalent meningococcal vaccine Menveo of Novartis Pharmaceutical Corp. as announced by the company on February 22, 2010 which allows its marketing of the vaccine.

  • DSP Clinical and DIA Will Host Webinar, "Taking the Risk Out of Risk-Based Monitoring".  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article offers information on a webinar of the U.S. Food and Drug Administration and Ferring Pharmaceuticals to be held on July 31, 2012.

  • IBS-Drug Treatment Pulled, CV Side Effects. Elliott, William T. // Critical Care Alert;May2007 Pharmacology Watch, p1 

    The article reports on the removal from the market of tegaserod, a drug for irritable bowel syndrome from Novartis Pharmaceutical, by the U.S. Food and Drug Administration (FDA) after recent findings associated the drug with increased risk of cardiovascular (CV) events.

  • Mo. Plains facility sold to Novartis in $43M deal. Kaltwasser, Jared // njbiz;12/24/2012, p2 

    The article announces the sale of biotechnology company Dendreon Corp.'s immunotherapy manufacturing facility in Morris Plains, New Jersey, to Novartis Pharmaceuticals Corp. for 43 million U.S. dollars in cash.

  • GILENYA.  // MPR - Pharmacist's Edition;Winter2010/2011, Vol. 4 Issue 4, pA.5 

    The article evaluates Gilenya from Novartis Pharmaceuticals Corp.

  • Direct-to-consumer advertising touts free samples. Rose, Joan R. // Medical Economics;12/3/2001, Vol. 78 Issue 23, p14 

    Focuses on vouchers for free drug samples offered through the Internet by Novartis Pharmaceuticals and MedManage Systems. Benefits from the vouchers.

  • FDA approves new drug for children, adults with epilepsy.  // Hudson Valley Business Journal;01/31/2000, Vol. 10 Issue 25, p18 

    Reports that Novartis Pharmaceuticals Corp.'s Trileptal oxcarbazepine tablets has been approved by the United States Food and Drug Administration for marketing. Use of the drug for treating partial seizures in adults and children.

  • Renin inhibitor for high BP.  // Cortlandt Forum;May2007, Vol. 20 Issue 5, p16 

    The article provides information on the drug Tekturna, manufactured by Novartis Pharmaceutical Corp. The drug's active ingredient is aliskiren, which is an orally active, nonpeptide, potent direct renin inhibitor that decreases plasma renin activity. The drug is indicated for the treatment of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics